| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer
1 company
Henry R. Lambert last filed a Form 4 in August 2018, as Chief Executive Officer at PURE. Henry R. Lambert's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 698,056 shares of PURE. The PURE filings lean toward selling, a net 44,801 shares.
Henry R. Lambert has 8 Form 4 filings on record from July 2015 to August 2018, all as Chief Executive Officer at Pure Bioscience (PURE), 2015–2018.
The 14 reported transactions were 7 open-market sales, 4 option or other derivative awards and 3 stock awards.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $42K.
The largest open-market sale was 41,500 shares of PURE at an average $0.93 on January 12, 2018, about $39K.
Shares as reported in the last Form 4 for each company; the most recent is from August 2018. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.